SENS Sensyne Health

Sensyne Health appoints President, North America, to lead US expansion

Sensyne Health appoints President, North America, to lead US expansion

Sensyne Health appoints President, North America, to

lead US expansion      

Oxford, U.K. 13 November 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company’s North American operations, building Sensyne’s presence in the US and recruiting a US-based team.

Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing roles at Zynx Health and ambulatory electronic health records provider Practice Partner.

Derek is a US national and will be based in the US.    

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted that Derek is joining the Sensyne team. His extensive experience, combined with a deep knowledge of US healthcare technology and US health systems, will be invaluable as we further capitalise on what we have already achieved in the UK by driving forward our expansion into the US and building a transatlantic business.” 

Derek Baird, said:

“I’ve been impressed with the progress that Sensyne has already made in the UK in such a short space of time. It is clear the value that Sensyne delivers in the UK is equally applicable to US heathcare systems and life sciences companies. I’m excited to bring the Sensyne vision and unique business model to the US market.”

-ENDS-

For more information please contact:

Sensyne Health ()+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer 
Michael Norris, Interim Chief Financial Officer 
Consilium Strategic Communications+44 (0) 7780 600290
Mary-Jane Elliott 
Sukaina Virji 
Melissa Gardiner 
 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit:

EN
13/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sensyne Health

 PRESS RELEASE

Form 8.3 - Lupus alpha Asset Management AG: Sensyne Health PLC

Lupus alpha Asset Management AG (-) 13-Apr-2022 / 18:00 CET/CEST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1. KEY INFORMATION   (a) Full name of discloser: Lupus alpha Asset Management AG (b) Owner or controller of interests and short positions disclosed, if different fro...

 PRESS RELEASE

Sensyne grows medical research dataset to 60 million patients

OXFORD, England--(BUSINESS WIRE)-- Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the ethical Clinical AI company, today announces that it has reached a milestone of access to a combined clinical research, clinical trial and real world de-identified and anonymized dataset of over 60 million patients. This enlarged dataset results from both Sensyne’s investment in virtual clinical development company, Phesi Inc. in January 2021, and the progress made by Sensyne and Phesi in building their respective data platforms. Between December 2020 and July 2021 Phesi grew its...

 PRESS RELEASE

Sensyne Health plc Appointment of Chief Scientific Officer

Sensyne Health plc Appointment of Chief Scientific Officer Appointment of Chief Scientific OfficerDr. David Ruau joins Sensyne Health from Bayer Pharmaceuticals Oxford, U.K. 22 July 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the ethical AI company, today announces the appointment of Dr David Ruau to the newly created role of Chief Scientific Officer with effect from 01 September 2021. In this role, David will lead the research effort at Sensyne aimed at applying ethical AI to the improvement of patient care and the discovery and development of new medicines. Dr Dav...

 PRESS RELEASE

Sensyne Health Interim Results

Sensyne Health Interim Results Sensyne Health Interim Results Oxford, UK; 21 January 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces its Interim Results for the six months ended 31 October 2020. Lord (Paul) Drayson, CEO of Sensyne Health, commented: “I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applyi...

 PRESS RELEASE

Sensyne Health appoints President, North America, to lead US expansion

Sensyne Health appoints President, North America, to lead US expansion Sensyne Health appoints President, North America, to lead US expansion       Oxford, U.K. 13 November 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company’s North American operations, building Sensyne’s presence in the US and recruiting a US-based...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch